ANGPTL3 and fatty liver disease: In a phase I basket study, single- and repeat-dose cohorts in healthy adults and individuals with hepatic steatosis showed that, in healthy participants, by day 85 after a single injection ANGPTL3 decreased by 45–78%, TG by 34–54%, and non–HDL-C by 18–29%.